Pfizer’s Humira biosimilar hits efficacy target
Pfizer has reported positive results from a trial of its monoclonal antibody PF-06410293, which the firm is developing as a biosimilar of AbbVie’s blockbuster Humira.
Read More
Pfizer has reported positive results from a trial of its monoclonal antibody PF-06410293, which the firm is developing as a biosimilar of AbbVie’s blockbuster Humira.
Read More
